Cerenome, through its subsidiary CNSide Diagnostics, secured an in-network agreement with Florida Blue to cover CNSide's cerebrospinal fluid (CSF) tumor cell enumeration and molecular profile tests. This deal adds about 6 million covered lives, expanding CNSide's payer network to approximately 164 million. The agreement marks the first to include both tumor cell and molecular profiling tests, enhancing CNSide's diagnostic platform for central nervous system cancers. CNSide's molecular profiling tests, now commercially available, support better cancer characterization and monitoring, backed by clinical studies and real-world data. This expansion aligns with Cerenome's strategy to broaden access and improve CNS cancer diagnostics nationwide.
Cerenome's recent agreement with Florida Blue provides context for health sector activity on Pluang. As of Oct 08, 2026 18:11 WIB, 25 out of 100 health stocks rose while 68 fell. Notable movers include TXG at USD 73.85 with a -2.96% change and 74% sell orders, SANA at USD 2.80 with a +2.94% change and 73% buy orders, and RXRX at USD 4.15 with a -2.81% change and 95% sell orders.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
